Bavarian Nordic A/S Announces Annual General Meeting
Copenhagen, Denmark, March 12, 2025 – In accordance with Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are cordially invited to attend the Annual General Meeting (AGM) to be held on May 25, 2025, at 10:00 a.m. CET, at the company’s headquarters located at Øster Farimagsgade 5, 1353 Copenhagen K, Denmark.
Agenda
The following items will be addressed during the AGM:
- Review of the annual report, including the consolidated financial statements and the report of the Board of Directors and the auditor;
- Approval of the annual report;
- Resolution regarding the allocation of profit or loss as shown in the adopted balance sheet;
- Discharge of the members of the Board of Directors and the Executive Management;
- Election of members to the Board of Directors;
- Setting the remuneration for the members of the Board of Directors;
- Authorization of the Board of Directors to purchase own shares;
- Any other business.
Impact on Shareholders
Shareholders who wish to participate in the AGM must be registered in the share register maintained by the Danish Central Securities Depository (Danish: VP Securities Services A/S) on May 18, 2025. Proxy voting is allowed, and shareholders may appoint a proxy to attend and vote on their behalf.
Impact on the World
Bavarian Nordic A/S is a global biotech company focused on the development, manufacturing, and commercialization of vaccines and therapeutics for infectious diseases and cancer. The company’s mission is to save and improve lives through the power of science. The AGM is an essential event for the company, ensuring transparency and accountability to its shareholders and the public. Bavarian Nordic’s work in vaccine development, particularly its smallpox vaccine, has significant implications for global health security.
The AGM is an opportunity for shareholders to engage with the company’s management and ask questions regarding its operations, financial performance, and future plans. The election of new Board members and the approval of resolutions, such as the allocation of profits and the authorization to purchase own shares, are crucial decisions that can impact the company’s strategic direction and financial performance.
Conclusion
The Annual General Meeting of Bavarian Nordic A/S is an essential event for the company and its shareholders. It provides a platform for transparency, accountability, and engagement. Shareholders, particularly those who cannot attend in person, are encouraged to exercise their right to vote and engage with the company through proxy voting. The AGM’s outcomes will shape the company’s future direction and impact its shareholders, as well as the broader global health landscape.
For more information regarding the AGM, including instructions for proxy voting, please visit the company’s website or contact the company’s Investor Relations team.
